Literature DB >> 21813452

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.

Shabnam Kharazi1, Adam J Mead, Anna Mansour, Anne Hultquist, Charlotta Böiers, Sidinh Luc, Natalija Buza-Vidas, Zhi Ma, Helen Ferry, Debbie Atkinson, Kristian Reckzeh, Kristina Masson, Jörg Cammenga, Lars Rönnstrand, Fumio Arai, Toshio Suda, Claus Nerlov, Ewa Sitnicka, Sten Eirik W Jacobsen.   

Abstract

Acquisition of homozygous activating growth factor receptor mutations might accelerate cancer progression through a simple gene-dosage effect. Internal tandem duplications (ITDs) of FLT3 occur in approximately 25% cases of acute myeloid leukemia and induce ligand-independent constitutive signaling. Homozygous FLT3-ITDs confer an adverse prognosis and are frequently detected at relapse. Using a mouse knockin model of Flt3-internal tandem duplication (Flt3-ITD)-induced myeloproliferation, we herein demonstrate that the enhanced myeloid phenotype and expansion of granulocyte-monocyte and primitive Lin(-)Sca1(+)c-Kit(+) progenitors in Flt3-ITD homozygous mice can in part be mediated through the loss of the second wild-type allele. Further, whereas autocrine FLT3 ligand production has been implicated in FLT3-ITD myeloid malignancies and resistance to FLT3 inhibitors, we demonstrate here that the mouse Flt3(ITD/ITD) myeloid phenotype is FLT3 ligand-independent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813452     DOI: 10.1182/blood-2010-06-289207

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.

Authors:  J C T Loke; S Akiki; J Borrow; J Ewing; S W Bokhari; D Chandra; J Arrazi; P Hazlewood; K Arthur; J Walsh; Y Membwange; F A Wandroo; A Watts; A Borg; K Brock; P Ferguson; C Craddock; M Griffiths; M Raghavan
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

2.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Authors:  C D DiNardo; I S Tiong; A Quaglieri; S MacRaild; S Loghavi; F C Brown; R Thijssen; G Pomilio; A Ivey; J M Salmon; C Glytsou; S A Fleming; Q Zhang; H Ma; K P Patel; S M Kornblau; Z Xu; C C Chua; Xufeng Chen; P Blombery; C Flensburg; N Cummings; I Aifantis; H Kantarjian; D C S Huang; A W Roberts; I J Majewski; M Konopleva; A H Wei
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

3.  FLT3 ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche.

Authors:  Kirsten M Williams; Amber R Moore; Philip J Lucas; Juin Wang; Catherine V Bare; Ronald E Gress
Journal:  Exp Hematol       Date:  2017-05-26       Impact factor: 3.084

4.  Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.

Authors:  Yiting Lim; Lukasz Gondek; Li Li; Qiuju Wang; Hayley Ma; Haley Ma; Emily Chang; David L Huso; Sarah Foerster; Luigi Marchionni; Karen McGovern; David Neil Watkins; Craig D Peacock; Mark Levis; Bruce Douglas Smith; Akil A Merchant; Donald Small; William Matsui
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

Review 5.  Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Authors:  Yun Chen; Yihang Pan; Yao Guo; Wanke Zhao; Wanting Tina Ho; Jianlong Wang; Mingjiang Xu; Feng-Chun Yang; Zhizhuang Joe Zhao
Journal:  Stem Cell Investig       Date:  2017-06-02

6.  Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.

Authors:  Nicholas A Zorko; Kelsie M Bernot; Susan P Whitman; Ronald F Siebenaler; Elshafa H Ahmed; Gabriele G Marcucci; Daniel A Yanes; Kathleen K McConnell; Charlene Mao; Chidimma Kalu; Xiaoli Zhang; David Jarjoura; Adrienne M Dorrance; Nyla A Heerema; Benjamin H Lee; Gang Huang; Guido Marcucci; Michael A Caligiuri
Journal:  Blood       Date:  2012-06-06       Impact factor: 22.113

7.  Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.

Authors:  Sarah Greenblatt; Li Li; Christopher Slape; Bao Nguyen; Rachel Novak; Amy Duffield; David Huso; Stephen Desiderio; Michael J Borowitz; Peter Aplan; Donald Small
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

8.  NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.

Authors:  Rachel Rau; Daniel Magoon; Sarah Greenblatt; Li Li; Colleen Annesley; Amy S Duffield; David Huso; Emily McIntyre; John G Clohessy; Markus Reschke; Pier Paolo Pandolfi; Donald Small; Patrick Brown
Journal:  Exp Hematol       Date:  2013-10-29       Impact factor: 3.084

9.  TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality.

Authors:  Jue Wang; Tongjuan Li; Mi Zhou; Zheng Hu; Xiaoxi Zhou; Shiqiu Zhou; Na Wang; Liang Huang; Lei Zhao; Yang Cao; Min Xiao; Ding Ma; Pengfei Zhou; Zhen Shang; Jianfeng Zhou
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

10.  FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.

Authors:  Adam J Mead; Shabnam Kharazi; Deborah Atkinson; Iain Macaulay; Christian Pecquet; Stephen Loughran; Michael Lutteropp; Petter Woll; Onima Chowdhury; Sidinh Luc; Natalija Buza-Vidas; Helen Ferry; Sally-Ann Clark; Nicolas Goardon; Paresh Vyas; Stefan N Constantinescu; Ewa Sitnicka; Claus Nerlov; Sten Eirik W Jacobsen
Journal:  Cell Rep       Date:  2013-05-30       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.